share_log

Intelligent Bio Solutions | 8-K: Current report

SEC announcement ·  Feb 8 06:08
Summary by Futu AI
On February 4, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol INBS, entered into warrant inducement agreements with certain holders of its Series E Warrants issued on October 4, 2023. The agreement allowed these holders to exercise their existing warrants and receive one-for-one replacement warrants, termed Series G Warrants, which are immediately exercisable and will expire after 5.5 years. The exercise of the existing warrants resulted in the issuance of 606,064 shares of common stock and generated gross proceeds of approximately $1.77 million for the company, before deducting closing costs and placement agent fees. The net proceeds are intended for working capital and general corporate purposes. The company has committed to filing a resale registration...Show More
On February 4, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol INBS, entered into warrant inducement agreements with certain holders of its Series E Warrants issued on October 4, 2023. The agreement allowed these holders to exercise their existing warrants and receive one-for-one replacement warrants, termed Series G Warrants, which are immediately exercisable and will expire after 5.5 years. The exercise of the existing warrants resulted in the issuance of 606,064 shares of common stock and generated gross proceeds of approximately $1.77 million for the company, before deducting closing costs and placement agent fees. The net proceeds are intended for working capital and general corporate purposes. The company has committed to filing a resale registration statement for the shares underlying the replacement warrants within 30 days and to make it effective within 180 days. Ladenburg Thalmann & Co. Inc. served as the placement agent for the transaction, receiving compensation including cash fees, management fees, legal fees, and purchase warrants. The Series G Warrants have an exercise price of $4.50 per share and are not intended to be listed on any securities exchange. The company also announced the transaction in a press release on February 5, 2024.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.